Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody

Journal of Virology

Volumn 84, Issue 19, 2010, Pages 10169-10181

  Nasser, Roudaina ^a,b   Pelegrin, Mireia ^a,b   Michaud, Henri Alexandre ^a,b   Plays, Marc ^a,b   Piechaczyk, Marc ^a,b   Gros, Laurent ^a,b  

^a INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

667 MONOCLONAL ANTIBODY; 672 MONOCLONAL ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN ANTIBODY; UNCLASSIFIED DRUG; EPITOPE; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG RECEPTOR BINDING; ERYTHROLEUKEMIA; FRIEND LEUKEMIA VIRUS; IMMUNOMODULATION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; VIRUS REPLICATION; AMINO ACID SEQUENCE; ANIMAL; CD8+ T LYMPHOCYTE; CHEMISTRY; DISEASE MODEL; GENETICS; IMMUNOLOGY; LEUKEMIA, EXPERIMENTAL; MOLECULAR GENETICS; NEWBORN; PATHOGENICITY; PHYSIOLOGY; RETROVIRIDAE INFECTIONS; RETROVIRUS; TUMOR VIRUS INFECTIONS;

MUS;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; EPITOPES; FRIEND MURINE LEUKEMIA VIRUS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN FC FRAGMENTS; LEUKEMIA, EXPERIMENTAL; MICE; MOLECULAR SEQUENCE DATA; RETROVIRIDAE; RETROVIRIDAE INFECTIONS; TUMOR VIRUS INFECTIONS; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

EID: 77956852951     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00568-10     Document Type: Article

References (83)

1. Adkins, B., C. Leclerc, and S. Marshall-Clarke. 2004. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 4:553-564.
2. Andrews, N. P., C. D. Pack, V. Vezys, G. N. Barber, and A. E. Lukacher. 2007. Early virus-associated bystander events affect the fitness of the CD8 T cell response to persistent virus infection. J. Immunol. 178:7267-7275.
3. Araujo-Jorge, T., M. T. Rivera, A. el Bouhdidi, M. Daeron, and Y. Carlier. 1993. An Fc gamma RII-, Fc gamma RIII-specific monoclonal antibody (2.4G2) decreases acute Trypanosoma cruzi infection in mice. Infect. Immun. 61:4925-4928.
4. Armbruster, C., G. M. Stiegler, B. A. Vcelar, W. Jager, N. L. Michael, N. Vetter, and H. W. Katinger. 2002. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 16:227-233.
5. Baba, T. W., V. Liska, R. Hofmann-Lehmann, J. Vlasak, W. Xu, S. Ayehunie, L. A. Cavacini, M. R. Posner, H. Katinger, G. Stiegler, B. J. Bernacky, T. A. Rizvi, R. Schmidt, L. R. Hill, M. E. Keeling, Y. Lu, J. E. Wright, T. C. Chou, and R. M. Ruprecht. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200-206.
6. Baldridge, J. R., and M. J. Buchmeier. 1992. Mechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: mother-to-baby transfer of humoral protection. J. Virol. 66:4252-4257.
7. Baudino, L., F. Nimmerjahn, S. Azeredo da Silveira, E. Martinez-Soria, T. Saito, M. Carroll, J. V. Ravetch, J. S. Verbeek, and S. Izui. 2008. Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J. Immunol. 180:1948-1953.
8. Belnoue, E., P. Fontannaz-Bozzotti, S. Grillet, P. H. Lambert, and C. A. Siegrist. 2007. Protracted course of lymphocytic choriomeningitis virus WE infection in early life: induction but limited expansion of CD8+ effector T cells and absence of memory CD8+ T cells. J. Virol. 81:7338-7350.
9. Burioni, R., M. Perotti, N. Mancini, and M. Clementi. 2008. Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs. J. Hepatol. 49:299-300.
10. Busch, D. H., and E. G. Pamer. 1999. T cell affinity maturation by selective expansion during infection. J. Exp. Med. 189:701-710.
11. Cekinovic, D., M. Golemac, E. P. Pugel, J. Tomac, L. Cicin-Sain, I. Slavuljica, R. Bradford, S. Misch, T. H. Winkler, M. Mach, W. J. Britt, and S. Jonjic. 2008. Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. J. Virol. 82:12172-12180.
12. Chen, W., H. Qin, B. Chesebro, and M. A. Cheever. 1996. Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J. Virol. 70:7773-7782.
13. Congy-Jolivet, N., A. Probst, H. Watier, and G. Thibault. 2007. Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Crit. Rev. Oncol. Hematol. 64:226-233.
14. Czub, M., S. Czub, F. J. McAtee, and J. L. Portis. 1991. Age-dependent resistance to murine retrovirus-induced spongiform neurodegeneration results from central nervous system-specific restriction of virus replication. J. Virol. 65:2539-2544.
15. Czub, S., W. P. Lynch, M. Czub, and J. L. Portis. 1994. Kinetic analysis of spongiform neurodegenerative disease induced by a highly virulent murine retrovirus. Lab. Investig. 70:711-723.
16. Dreja, H., L. Gros, S. Villard, E. Bachrach, A. Oates, C. Granier, T. Chardes, J. C. Mani, M. Piechaczyk, and M. Pelegrin. 2003. Monoclonal antibody 667 recognizes the variable region A motif of the ecotropic retrovirus CasBrE envelope glycoprotein and inhibits Env binding to the viral receptor. J. Virol. 77:10984-10993.
17. Fadel, S. A., L. G. Cowell, S. Cao, D. A. Ozaki, T. B. Kepler, D. A. Steeber, and M. Sarzotti. 2006. Neonate-primed CD8+ memory cells rival adultprimed memory cells in antigen-driven expansion and anti-viral protection. Int. Immunol. 18:249-257.
18. Fadel, S. A., D. A. Ozaki, and M. Sarzotti. 2002. Enhanced type 1 immunity after secondary viral challenge in mice primed as neonates. J. Immunol. 169:3293-3300.
19. Ferrantelli, F., R. A. Rasmussen, K. A. Buckley, P. L. Li, T. Wang, D. C. Montefiori, H. Katinger, G. Stiegler, D. C. Anderson, H. M. McClure, and R. M. Ruprecht. 2004. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J. Infect. Dis. 189:2167-2173.
20. Franchini, M., C. Abril, C. Schwerdel, C. Ruedl, M. Ackermann, and M. Suter. 2001. Protective T-cell-based immunity induced in neonatal mice by a single replicative cycle of herpes simplex virus. J. Virol. 75:83-89.
21. Gairin, J. E., H. Mazarguil, D. Hudrisier, and M. B. Oldstone. 1995. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J. Virol. 69:2297-2305.
22. Galun, E., N. A. Terrault, R. Eren, A. Zauberman, O. Nussbaum, D. Terkieltaub, M. Zohar, R. Buchnik, Z. Ackerman, R. Safadi, Y. Ashur, S. Misrachi, Y. Liberman, L. Rivkin, and S. Dagan. 2007. Clinical evaluation (phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J. Hepatol. 46:37-44.
23. Gros, L., H. Dreja, A. L. Fiser, M. Plays, M. Pelegrin, and M. Piechaczyk. 2005. Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment. J. Virol. 79:6272-6280. (Pubitemid 40617231)
24. Gros, L., M. Pelegrin, H. A. Michaud, S. Bianco, J. Hernandez, C. Jacquet, and M. Piechaczyk. 2008. Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice. J. Virol. 82:1339-1349.
25. Gros, L., M. Pelegrin, M. Plays, and M. Piechaczyk. 2006. Efficient mother-to-child transfer of antiretroviral immunity in the context of preclinical monoclonal antibody-based immunotherapy. J. Virol. 80:10191-10200.
26. Guyre, C. A., D. Gomes, K. A. Smith, J. M. Kaplan, and M. A. Perricone. 2008. Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies. J. Immunol. Methods 333:51-60.
27. Hessell, A. J., L. Hangartner, M. Hunter, C. E. Havenith, F. J. Beurskens, J. M. Bakker, C. M. Lanigan, G. Landucci, D. N. Forthal, P. W. Parren, P. A. Marx, and D. R. Burton. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:101-104.
28. Hessell, A. J., P. Poignard, M. Hunter, L. Hangartner, D. M. Tehrani, W. K. Bleeker, P. W. Parren, P. A. Marx, and D. R. Burton. 2009. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15:951-954.
29. Hessell, A. J., E. G. Rakasz, P. Poignard, L. Hangartner, G. Landucci, D. N. Forthal, W. C. Koff, D. I. Watkins, and D. R. Burton. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5:e1000433.
30. Hofmann-Lehmann, R., J. Vlasak, R. A. Rasmussen, S. Jiang, P. L. Li, T. W. Baba, D. C. Montefiori, B. J. Bernacky, T. A. Rizvi, R. Schmidt, L. R. Hill, M. E. Keeling, H. Katinger, G. Stiegler, L. A. Cavacini, M. R. Posner, and R. M. Ruprecht. 2002. Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. J. Med. Primatol. 31:109-119.
31. Hong, H. J., C. J. Ryu, H. Hur, S. Kim, H. K. Oh, M. S. Oh, and S. Y. Park. 2004. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology 318:134-141.
32. Huber, M., V. von Wyl, C. G. Ammann, H. Kuster, G. Stiegler, H. Katinger, R. Weber, M. Fischer, H. Stoiber, H. F. Gunthard, and A. Trkola. 2008. Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. J. Virol. 82:3834-3842.
33. Imai, M., C. Landen, R. Ohta, N. K. Cheung, and S. Tomlinson. 2005. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res. 65:10562-10568. (Pubitemid 41743751)
34. Kaetzel, C. S. 2005. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol. Rev. 206:83-99.
35. Kim, S. H., Y. W. Shin, K. W. Hong, K. H. Chang, K. H. Ryoo, S. H. Paik, J. M. Kim, B. Brotman, W. Pfahler, and A. M. Prince. 2008. Neutralization of hepatitis B virus (HBV) by human monoclonal antibody against HBV surface antigen (HBsAg) in chimpanzees. Antivir. Res. 79:188-191.
36. Klaus, G. G., M. B. Pepys, K. Kitajima, and B. A. Askonas. 1979. Activation of mouse complement by different classes of mouse antibody. Immunology 38:687-695.
37. Kovarik, J., M. Gaillard, X. Martinez, P. Bozzotti, P. H. Lambert, T. F. Wild, and C. A. Siegrist. 2001. Induction of adult-like antibody, Th1, and CTL responses to measles hemagglutinin by early life murine immunization with an attenuated vaccinia-derived NYVAC(K1L) viral vector. Virology 285:12-20.
38. Kummer, U., U. Zengerle, J. Pischel, B. Trautmann, R. Mailhammer, and N. Sidell. 2001. Increased in vivo mitogenicity of anti-TCR/CD3 monoclonal antibody through reduced interaction with Fcgamma receptors. Immunol. Lett. 75:153-158.
39. Kurlander, R. J., D. M. Ellison, and J. Hall. 1984. The blockade of Fc receptor-mediated clearance of immune complexes in vivo by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes. J. Immunol. 133:855-862.
40. Law, M., T. Maruyama, J. Lewis, E. Giang, A. W. Tarr, Z. Stamataki, P. Gastaminza, F. V. Chisari, I. M. Jones, R. I. Fox, J. K. Ball, J. A. McKeating, N. M. Kneteman, and D. R. Burton. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14:25-27.
41. Lynch, W. P., S. J. Robertson, and J. L. Portis. 1995. Induction of focal spongiform neurodegeneration in developmentally resistant mice by implantation of murine retrovirus-infected microglia. J. Virol. 69:1408-1419.
42. Manrique, A., P. Rusert, B. Joos, M. Fischer, H. Kuster, C. Leemann, B. Niederost, R. Weber, G. Stiegler, H. Katinger, H. F. Gunthard, and A. Trkola. 2007. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J. Virol. 81:8793-8808.
43. Marasco, W. A., and J. Sui. 2007. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat. Biotechnol. 25:1421-1434.
44. McAtee, F. J., and J. L. Portis. 1985. Monoclonal antibodies specific for wild mouse neurotropic retrovirus: detection of comparable levels of virus replication in mouse strains susceptible and resistant to paralytic disease. J. Virol. 56:1018-1022.
45. Mejías, A., and O. Ramilo. 2008. Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants. Biologics 2:433-439.
46. Michaud, H. Gomard, T. Gros, L. Thiolon, K. Nasser, R. Jacquet, C. Hernandez, J. Piechaczyck, M., and M. Pelgrin. 2010. A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog. 6:e1000948.
47. Molina, F., D. Laune, C. Gougat, B. Pau, and C. Granier. 1996. Improved performances of spot multiple peptide synthesis. Pept. Res. 9:151-155.
48. Morrey, J. D., V. Siddharthan, H. Wang, J. O. Hall, R. T. Skirpstunas, A. L. Olsen, J. L. Nordstrom, S. Koenig, S. Johnson, and M. S. Diamond. 2008. West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons. J. Neurovirol. 14:152-163.
49. Mozdzanowska, K., J. Feng, and W. Gerhard. 2003. Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice. J. Virol. 77:8322-8328.
50. Nakowitsch, S., H. Quendler, H. Fekete, R. Kunert, H. Katinger, and G. Stiegler. 2005. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies. AIDS 19:1957-1966.
51. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8:34-47.
52. Ohlén, C., M. Kalos, L. E. Cheng, A. C. Shur, D. J. Hong, B. D. Carson, N. C. Kokot, C. G. Lerner, B. D. Sather, E. S. Huseby, and P. D. Greenberg. 2002. CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J. Exp. Med. 195:1407-1418.
53. Oliphant, T., M. Engle, G. E. Nybakken, C. Doane, S. Johnson, L. Huang, S. Gorlatov, E. Mehlhop, A. Marri, K. M. Chung, G. D. Ebel, L. D. Kramer, D. H. Fremont, and M. S. Diamond. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11:522-530.
54. Oliphant, T., G. E. Nybakken, M. Engle, Q. Xu, C. A. Nelson, S. Sukupolvi-Petty, A. Marri, B. E. Lachmi, U. Olshevsky, D. H. Fremont, T. C. Pierson, and M. S. Diamond. 2006. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J. Virol. 80:12149-12159.
55. Parren, P. W., P. A. Marx, A. J. Hessell, A. Luckay, J. Harouse, C. Cheng-Mayer, J. P. Moore, and D. R. Burton. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-8347.
56. Pelegrin, M., M. Marin, A. Oates, D. Noel, R. Saller, B. Salmons, and M. Piechaczyk. 2000. Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies. Hum. Gene Ther. 11:1407-1415.
57. Poignard, P., R. Sabbe, G. R. Picchio, M. Wang, R. J. Gulizia, H. Katinger, P. W. Parren, D. E. Mosier, and D. R. Burton. 1999. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10:431-438.
58. Portis, J. L., S. Czub, C. F. Garon, and F. J. McAtee. 1990. Neurodegenerative disease induced by the wild mouse ecotropic retrovirus is markedly accelerated by long terminal repeat and gag-pol sequences from nondefective Friend murine leukemia virus. J. Virol. 64:1648-1656.
59. Prabakaran, M., N. Prabhu, F. He, Q. Hongliang, H. T. Ho, J. Qiang, T. Meng, M. Goutama, and J. Kwang. 2009. Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS One 4:e5672.
60. Prabhu, N., M. Prabakaran, H. T. Ho, S. Velumani, J. Qiang, M. Goutama, and J. Kwang. 2009. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J. Virol. 83:2553-2562.
61. Rees, W., J. Bender, T. K. Teague, R. M. Kedl, F. Crawford, P. Marrack, and J. Kappler. 1999. An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. Proc. Natl. Acad. Sci. U. S. A. 96:9781-9786.
62. Reichert, J. M. 2008. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol. 9:423-430.
63. Reichert, J. M. 2007. Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs 21:1-7.
64. Reichert, J. M., C. J. Rosensweig, L. B. Faden, and M. C. Dewitz. 2005. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23:1073-1078.
65. Ridge, J. P., E. J. Fuchs, and P. Matzinger. 1996. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 271:1723-1726.
66. Sarzotti, M., D. S. Robbins, and P. M. Hoffman. 1996. Induction of protective CTL responses in newborn mice by a murine retrovirus. Science 271:1726-1728.
67. Savage, P. A., J. J. Boniface, and M. M. Davis. 1999. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 10:485-492.
68. Schepers, K., M. Toebes, G. Sotthewes, F. A. Vyth-Dreese, T. A. Dellemijn, C. J. Melief, F. Ossendorp, and T. N. Schumacher. 2002. Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J. Immunol. 169:3191-3199.
69. Schlesinger, J. J., and S. Chapman. 1995. Neutralizing F(ab′)2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J. Gen. Virol. 76:217-220.
70. Shibuya, A., N. Sakamoto, Y. Shimizu, K. Shibuya, M. Osawa, T. Hiroyama, H. J. Eyre, G. R. Sutherland, Y. Endo, T. Fujita, T. Miyabayashi, S. Sakano, T. Tsuji, E. Nakayama, J. H. Phillips, L. L. Lanier, and H. Nakauchi. 2000. Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes. Nat. Immunol. 1:441-446.
71. Siegrist, C. A., and R. Aspinall. 2009. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 9:185-194.
72. Siegrist, C. A., F. Saddallah, C. Tougne, X. Martinez, J. Kovarik, and P. H. Lambert. 1998. Induction of neonatal TH1 and CTL responses by live viral vaccines: a role for replication patterns within antigen presenting cells? Vaccine 16:1473-1478.
73. Simmons, C. P., N. L. Bernasconi, A. L. Suguitan, K. Mills, J. M. Ward, N. V. Chau, T. T. Hien, F. Sallusto, Q. Ha do, J. Farrar, M. D. de Jong, A. Lanzavecchia, and K. Subbarao. 2007. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 4:e178.
74. Sui, J., W. C. Hwang, S. Perez, G. Wei, D. Aird, L. M. Chen, E. Santelli, B. Stec, G. Cadwell, M. Ali, H. Wan, A. Murakami, A. Yammanuru, T. Han, N. J. Cox, L. A. Bankston, R. O. Donis, R. C. Liddington, and W. A. Marasco. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16:265-273.
75. Takada, A., H. Ebihara, S. Jones, H. Feldmann, and Y. Kawaoka. 2007. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 25:993-999. (Pubitemid 44937459)
76. Trkola, A., H. Kuster, P. Rusert, B. Joos, M. Fischer, C. Leemann, A. Manrique, M. Huber, M. Rehr, A. Oxenius, R. Weber, G. Stiegler, B. Vcelar, H. Katinger, L. Aceto, and H. F. Gunthard. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11:615-622.
77. Trkola, A., H. Kuster, P. Rusert, V. von Wyl, C. Leemann, R. Weber, G. Stiegler, H. Katinger, B. Joos, and H. F. Gunthard. 2008. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J. Virol. 82:1591-1599.
78. Veazey, R. S., R. J. Shattock, M. Pope, J. C. Kirijan, J. Jones, Q. Hu, T. Ketas, P. A. Marx, P. J. Klasse, D. R. Burton, and J. P. Moore. 2003. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9:343-346.
79. Walker, L. M., S. K. Phogat, P. Y. Chan-Hui, D. Wagner, P. Phung, J. L. Goss, T. Wrin, M. D. Simek, S. Fling, J. L. Mitcham, J. K. Lehrman, F. H. Priddy, O. A. Olsen, S. M. Frey, P. W. Hammond, G. Miiro, J. Serwanga, A. Pozniak, D. McPhee, O. Manigart, L. Mwananyanda, E. Karita, A. Inwoley, W. Jaoko, J. Dehovitz, L. G. Bekker, P. Pitisuttithum, R. Paris, S. Allen, S. Kaminsky, T. Zamb, M. Moyle, W. C. Koff, P. Poignard, and D. R. Burton. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
80. Zhu, Z., K. N. Bossart, K. A. Bishop, G. Crameri, A. S. Dimitrov, J. A. McEachern, Y. Feng, D. Middleton, L. F. Wang, C. C. Broder, and D. S. Dimitrov. 2008. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J. Infect. Dis. 197:846-853.
81. Zhu, Z., S. Chakraborti, Y. He, A. Roberts, T. Sheahan, X. Xiao, L. E. Hensley, P. Prabakaran, B. Rockx, I. A. Sidorov, D. Corti, L. Vogel, Y. Feng, J. O. Kim, L. F. Wang, R. Baric, A. Lanzavecchia, K. M. Curtis, G. J. Nabel, K. Subbarao, S. Jiang, and D. S. Dimitrov. 2007. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 104:12123-12128.
82. Zhu, Z., A. S. Dimitrov, K. N. Bossart, G. Crameri, K. A. Bishop, V. Choudhry, B. A. Mungall, Y. R. Feng, A. Choudhary, M. Y. Zhang, Y. Feng, L. F. Wang, X. Xiao, B. T. Eaton, C. C. Broder, and D. S. Dimitrov. 2006. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J. Virol. 80:891-899.
83. Zhu, Z., A. S. Dimitrov, S. Chakraborti, D. Dimitrova, X. Xiao, C. C. Broder, and D. S. Dimitrov. 2006. Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses. Expert Rev. Anti Infect. Ther. 4:57-66.